These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34370650)

  • 1. Are Lysosomes Potential Therapeutic Targets for Parkinson's Disease?
    Petese A; Cesaroni V; Cerri S; Blandini F
    CNS Neurol Disord Drug Targets; 2022; 21(8):642-655. PubMed ID: 34370650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
    Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation.
    Jinn S; Drolet RE; Cramer PE; Wong AH; Toolan DM; Gretzula CA; Voleti B; Vassileva G; Disa J; Tadin-Strapps M; Stone DJ
    Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2389-2394. PubMed ID: 28193887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Lysosomal Exocytosis Induced by Lysosomal Ca
    Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D
    J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trends in basic research on Parkinson's disease: from mitochondria, lysosome to α-synuclein.
    Matsui H; Takahashi R
    J Neural Transm (Vienna); 2024 Jun; 131(6):663-674. PubMed ID: 38613675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export.
    Martin S; Smolders S; Van den Haute C; Heeman B; van Veen S; Crosiers D; Beletchi I; Verstraeten A; Gossye H; Gelders G; Pals P; Hamouda NN; Engelborghs S; Martin JJ; Eggermont J; De Deyn PP; Cras P; Baekelandt V; Vangheluwe P; Van Broeckhoven C;
    Acta Neuropathol; 2020 Jun; 139(6):1001-1024. PubMed ID: 32172343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomal response in relation to α-synuclein pathology differs between Parkinson's disease and multiple system atrophy.
    Puska G; Lutz MI; Molnar K; Regelsberger G; Ricken G; Pirker W; Laszlo L; Kovacs GG
    Neurobiol Dis; 2018 Jun; 114():140-152. PubMed ID: 29505813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acidic nanoparticles protect against α-synuclein-induced neurodegeneration through the restoration of lysosomal function.
    Arotcarena ML; Soria FN; Cunha A; Doudnikoff E; Prévot G; Daniel J; Blanchard-Desce M; Barthélémy P; Bezard E; Crauste-Manciet S; Dehay B
    Aging Cell; 2022 Apr; 21(4):e13584. PubMed ID: 35318803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-faceted genotoxic network of alpha-synuclein in the nucleus and mitochondria of dopaminergic neurons in Parkinson's disease: Emerging concepts and challenges.
    Vasquez V; Mitra J; Wang H; Hegde PM; Rao KS; Hegde ML
    Prog Neurobiol; 2020 Feb; 185():101729. PubMed ID: 31863801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction.
    Bellomo G; Paciotti S; Gatticchi L; Parnetti L
    Mov Disord; 2020 Jan; 35(1):34-44. PubMed ID: 31729779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emerging Role of the Lysosome in Parkinson's Disease.
    Navarro-Romero A; Montpeyó M; Martinez-Vicente M
    Cells; 2020 Nov; 9(11):. PubMed ID: 33147750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
    Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-Synuclein and the Endolysosomal System in Parkinson's Disease: Guilty by Association.
    Teixeira M; Sheta R; Idi W; Oueslati A
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies.
    Dai L; Liu M; Ke W; Chen L; Fang X; Zhang Z
    Cell Mol Life Sci; 2024 Sep; 81(1):382. PubMed ID: 39223418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
    McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
    J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.
    Nguyen M; Wong YC; Ysselstein D; Severino A; Krainc D
    Trends Neurosci; 2019 Feb; 42(2):140-149. PubMed ID: 30509690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.